Email Updates

Search form

You are here

iPrEx OLE

Status
Completed
Phase
Open Label
Objective

Continuation of the iPrEx study designed to provide additional information about the safety of PrEP and the behavior of people taking PrEP over a longer term.

**Results show PrEP provides a high degree of protection against HIV infection, even for individuals who miss some daily doses; high Interest in PrEP; longer-term evidence of safety and efficacy; and no sign of increased risk behavior among PrEP users.**
Prevention Option(s)
PrEP
Trial Sponsors
DAIDS/NIH, through a grant to the Gladstone Institutes
Population
MSM
Sites

Investigaciones Medicas en Salud (INMENSA)

Lima
Peru

Asociación Civil Selva Amazónica (ACSA)

Iquitos
Peru

San Francisco Department of Public Health

San Francisco, California
United States of America

Fenway Community Health Clinical Research Site (FCHCRS)

Boston, Massachusetts
United States of America

Ruth M Rothstein CORE Center

Chicago
United States of America

Universidade de São Paulo

Sao Paulo
Brazil

Instituto de Pesquisa Clínica Evandro Chagas

Rio de Janeiro
Brazil

Universidade Federal do Rio de Janeiro

Rio de Janeiro
Brazil

Research Institute for the Health Sciences

Chiang Mai
Thailand

Emavundleni Desmond Tutu HIV Centre CRS

Cape Town
South Africa

Fundación Ecuatoriana Equidad

Guayaquil
Ecuador